Skip to content

Study · Randomized controlled trial · 2003

4 results

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD

Journal of the National Cancer Institute1 Dec 2003Cited by 172 (Europe PMC)

PMID14679153 (opens in a new tab)DOI10.1093/jnci/djg119 (opens in a new tab)PepBankPUB-14679153
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with ER-negative, node-negative breast cancer, five-year disease-free survival was 73% with goserelin alone versus 84% with CMF alone.

    In plain wordsIn women with ER-negative breast cancer, five-year disease-free survival was lower with goserelin alone than CMF alone.

    Peptide
    Goserelin
    Outcome
    DecreaseFive-year disease-free survival
    Study

    n: not reported in source

    Comparator
    CMF chemotherapy alone
    Analysis
    Primary
    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Measurements

    Five-year DFS
    73%
    goserelin alone
    DFS confidence interval lower
    64%
    goserelin alone
    DFS confidence interval upper
    81%
    goserelin alone
    Five-year DFS
    84%
    CMF alone
    DFS confidence interval lower
    77%
    CMF alone
    DFS confidence interval upper
    91%
    CMF alone

    Source sentences

    Summary
    Patients with ER-negative tumors achieved better disease-free survival if they received CMF (5-year DFS for CMF = 84%, 95% confidence interval [CI] = 77% to 91%; 5-year DFS for CMF --> goserelin = 88%, 95% CI = 82% to 94%) than if they received goserelin alone (5-year DFS = 73%, 95% CI = 64% to 81%).
    2 context sentences
    Summary · context
    From March 1990 through October 1999, 1063 patients stratified by estrogen receptor (ER) status and radiotherapy plan were randomly assigned to receive goserelin for 24 months (n = 346)
    Summary · context
    The primary outcome was disease-free survival (DFS).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with ER-positive, node-negative breast cancer, goserelin alone and CMF alone produced similar five-year disease-free survival of 81% (95% CI 76% to 87%).

    In plain wordsIn women with ER-positive breast cancer, five-year disease-free survival was similar with goserelin alone and CMF alone.

    Peptide
    Goserelin
    Outcome
    Not applicableFive-year disease-free survival
    Study

    n: not reported in source

    Comparator
    CMF chemotherapy alone
    Analysis
    Primary
    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    Dose not stated · 24 monthsAs given in this study (human).

    Measurements

    Five-year DFS
    81%
    both monotherapy groups
    DFS confidence interval lower
    76%
    both monotherapy groups
    DFS confidence interval upper
    87%
    both monotherapy groups

    Source sentences

    Summary
    By contrast, for patients with ER-positive disease, chemotherapy alone and goserelin alone provided similar outcomes (5-year DFS for both treatment groups = 81%, 95% CI = 76% to 87%)
    2 context sentences
    Summary · context
    From March 1990 through October 1999, 1063 patients stratified by estrogen receptor (ER) status and radiotherapy plan were randomly assigned to receive goserelin for 24 months (n = 346)
    Summary · context
    The primary outcome was disease-free survival (DFS).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with ER-positive, node-negative breast cancer, sequential CMF then goserelin had five-year disease-free survival of 86% (95% CI 82% to 91%), a statistically nonsignificant improvement compared with either CMF alone or goserelin alone.

    In plain wordsIn women with ER-positive breast cancer, CMF followed by goserelin gave a statistically nonsignificant improvement in five-year disease-free survival compared with either treatment alone.

    Peptide
    Goserelin
    Outcome
    No significant changeFive-year disease-free survival
    Study

    n: not reported in source

    Comparator
    either CMF alone or goserelin alone
    Analysis
    Primary
    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    Dose not stated · 18 months after six courses of CMFAs given in this study (human).

    Measurements

    Five-year DFS
    86%
    CMF then goserelin
    DFS confidence interval lower
    82%
    CMF then goserelin
    DFS confidence interval upper
    91%
    CMF then goserelin

    Source sentences

    Summary
    whereas sequential therapy (5-year DFS = 86%, 95% CI = 82% to 91%) provided a statistically nonsignificant improvement compared with either modality alone, primarily because of the results among younger women.
    2 context sentences
    Summary · context
    or six courses of classical CMF followed by 18 months of goserelin (CMF --> goserelin; n = 357).
    Summary · context
    The primary outcome was disease-free survival (DFS).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with ER-negative, node-negative breast cancer, five-year disease-free survival was 88% with CMF then goserelin versus 84% with CMF alone.

    In plain wordsIn women with ER-negative breast cancer, five-year disease-free survival was 88% with CMF then goserelin versus 84% with CMF alone.

    Peptide
    Goserelin
    Outcome
    IncreaseFive-year disease-free survival in ER-negative disease
    Study

    n: not reported in source

    Comparator
    CMF chemotherapy alone
    Analysis
    Primary
    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    Dose not stated · 18 months after six courses of CMFAs given in this study (human).

    Measurements

    Five-year DFS
    88%
    CMF then goserelin
    DFS confidence interval lower
    82%
    CMF then goserelin
    DFS confidence interval upper
    94%
    CMF then goserelin
    Five-year DFS
    84%
    CMF alone
    DFS confidence interval lower
    77%
    CMF alone
    DFS confidence interval upper
    91%
    CMF alone

    Source sentences

    Summary
    Patients with ER-negative tumors achieved better disease-free survival if they received CMF (5-year DFS for CMF = 84%, 95% confidence interval [CI] = 77% to 91%; 5-year DFS for CMF --> goserelin = 88%, 95% CI = 82% to 94%)
    2 context sentences
    Summary · context
    or six courses of classical CMF followed by 18 months of goserelin (CMF --> goserelin; n = 357).
    Summary · context
    The primary outcome was disease-free survival (DFS).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.